HUP9702477A2 - A doxazosin-mezilát új polimorf módosulata (III. forma), eljárás előállítására és a vegyületet tartalmazó gyógyszerkészítmények - Google Patents

A doxazosin-mezilát új polimorf módosulata (III. forma), eljárás előállítására és a vegyületet tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9702477A2
HUP9702477A2 HU9702477A HUP9702477A HUP9702477A2 HU P9702477 A2 HUP9702477 A2 HU P9702477A2 HU 9702477 A HU9702477 A HU 9702477A HU P9702477 A HUP9702477 A HU P9702477A HU P9702477 A2 HUP9702477 A2 HU P9702477A2
Authority
HU
Hungary
Prior art keywords
iii
doxazosin
mesylate
preparation
pharmaceutical compositions
Prior art date
Application number
HU9702477A
Other languages
English (en)
Inventor
Ingomar Grafe
Johann Peter Mörsdorf
Original Assignee
Heumann Pharma Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8223531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9702477(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Heumann Pharma Gmbh. filed Critical Heumann Pharma Gmbh.
Publication of HU9702477D0 publication Critical patent/HU9702477D0/hu
Publication of HUP9702477A2 publication Critical patent/HUP9702477A2/hu
Publication of HUP9702477A3 publication Critical patent/HUP9702477A3/hu
Publication of HU228306B1 publication Critical patent/HU228306B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány tárgya a III. főrmájú dőxazősin-mezilát - kémiai neve: 1-(4-aminő-6,7-dimetőxi-2-kinazőlinil)-4-[(2,3-dihidrő-1,4-benződi-őxin-2-il)-karbőnil-piperazin-metánszűlfőnát -, amelynek kristálypőrőnfelvett röntgendiagrammja az alábbi, jellemző, nagy és közepesintenzitású visszaverődési helyeket műtatja: 8,49ř, 11,72ř 16,03ř18,29ř 21,03ř 22,87ř 25,02ř tővábbá kristályős és vízmentes. Atalálmány tővábbá a fenti III. főrma előállítási eljárására isvőnatkőzik. A találmány szerinti III. kristályfőrma mind kristályős sajátságai,mind előállítási eljárásnak könnyedsége, mind galenikűsfeldőlgőzásának szempőntjai szerint előnyöket műtat. A találmány azőkra a gyógyszerekre is vőnatkőzik, amelyek dőxazősin-mezilát III. főrmáját a szőkásős vivő- és segédanyagőkkal együtttartalmazzák. ŕ
HU9702477A 1996-12-20 1997-12-16 Polymorph form of doxazosin-mesylate and pharmaceutical compositions containing the same HU228306B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96120603A EP0849266B8 (de) 1996-12-20 1996-12-20 Neue polymorphe Form von Doxazosinmesylat (Form III)

Publications (4)

Publication Number Publication Date
HU9702477D0 HU9702477D0 (en) 1998-03-02
HUP9702477A2 true HUP9702477A2 (hu) 1999-04-28
HUP9702477A3 HUP9702477A3 (en) 1999-06-28
HU228306B1 HU228306B1 (en) 2013-03-28

Family

ID=8223531

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9702477A HU228306B1 (en) 1996-12-20 1997-12-16 Polymorph form of doxazosin-mesylate and pharmaceutical compositions containing the same

Country Status (16)

Country Link
US (1) US6140334A (hu)
EP (1) EP0849266B8 (hu)
JP (1) JP4657393B2 (hu)
KR (1) KR100659927B1 (hu)
AT (1) ATE353892T1 (hu)
AU (1) AU725253B2 (hu)
CA (1) CA2225022C (hu)
DE (1) DE59611417D1 (hu)
DK (1) DK0849266T3 (hu)
ES (1) ES2282997T3 (hu)
HU (1) HU228306B1 (hu)
IL (1) IL122630A (hu)
NZ (1) NZ329406A (hu)
PT (1) PT849266E (hu)
TW (1) TW442484B (hu)
ZA (1) ZA9710634B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
DE19800214A1 (de) * 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür
ES2164520B1 (es) * 1999-03-16 2003-04-01 Medichem Sa "procedimiento de obtencion del polimorfo a del mesilato de doxazosina"
DE19912063A1 (de) * 1999-03-18 2000-09-21 Knoll Ag Neues Verfahren zur Herstellung von Doxazosin-Mesylat in einer als Form A bezeichneten Kristallmodifikation
DE19912573A1 (de) * 1999-03-19 2000-09-21 Knoll Ag Arzneimittel, enthaltend Doxazosin-Mesylat der Kristallmodifikaton D
AU2008339652B2 (en) 2007-12-24 2013-07-04 Cipla Limited Crystalline polymorph of doxazosin mesylate (form IV) and process for preparation thereof
CN109988158A (zh) * 2018-01-03 2019-07-09 合肥立方制药股份有限公司 X晶型、含有x晶型的多沙唑嗪甲磺酸盐及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699054A (en) * 1953-10-09 1955-01-11 Lloyd H Conover Tetracycline
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
DK154082C (da) * 1977-11-05 1989-02-27 Pfizer Analogifremgangsmaade til fremstilling af 4-amino-6,7-dimethoxy-2-(piperazin-1-yl eller homopiperazin-1-yl)-quinazolinforbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DE3683760D1 (de) * 1986-03-21 1992-03-12 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2-furoyl-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
DK0459666T3 (da) * 1990-05-31 1994-12-05 Pfizer Lægemidler mod impotens
WO1994009783A1 (en) * 1992-11-04 1994-05-11 Sepracor, Inc. Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)

Also Published As

Publication number Publication date
HU9702477D0 (en) 1998-03-02
EP0849266A1 (de) 1998-06-24
KR19980064288A (ko) 1998-10-07
PT849266E (pt) 2007-03-30
EP0849266B8 (de) 2007-10-03
DK0849266T3 (da) 2007-06-04
IL122630A0 (en) 1998-08-16
JP4657393B2 (ja) 2011-03-23
HU228306B1 (en) 2013-03-28
US6140334A (en) 2000-10-31
CA2225022C (en) 2008-10-07
DE59611417D1 (de) 2007-03-29
HUP9702477A3 (en) 1999-06-28
KR100659927B1 (ko) 2007-04-11
JPH10182641A (ja) 1998-07-07
ZA9710634B (en) 1998-11-11
TW442484B (en) 2001-06-23
ES2282997T3 (es) 2007-10-16
AU4844997A (en) 1998-06-25
NZ329406A (en) 1998-10-28
ATE353892T1 (de) 2007-03-15
EP0849266B1 (de) 2007-02-14
AU725253B2 (en) 2000-10-12
IL122630A (en) 2000-02-17
CA2225022A1 (en) 1998-06-20

Similar Documents

Publication Publication Date Title
DE69531457D1 (en) Sulfonamide
SE9404080L (sv) Förfarande för framställning av en optiskt ren enantiomer av formoterol
DE69310518D1 (de) Pharmazeutische zusammensetzung zur topischen anwendung die ein vernetztes kationisches polymer und einen alkoxylierte äther enthält
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
AR004961A1 (es) Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el
HUP9702477A2 (hu) A doxazosin-mezilát új polimorf módosulata (III. forma), eljárás előállítására és a vegyületet tartalmazó gyógyszerkészítmények
DE69518767D1 (de) Ondasetronhaltige oral anzuwendende arzneimittel
ATE228360T1 (de) Stabilisierte schilddrüsenhormonhaltige arzneimittel
NO173998C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
FI964097A0 (fi) Insektisidiset lannoiteseokset
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
PT92647A (pt) Processo para a preparacao de 5-cloro-2-< { (3,4-dimetoxi-2-piridinil)-metil}-sulfinil>-1h-benzimidazol e de composicoes farmaceuticas que o contem
HUP9702480A2 (hu) A doxazosin-mezilát új polimorf módosulata (I. forma), eljárás előállítására és a vegyületet tartalmazó gyógyszerkészítmények
CO4940452A1 (es) Modificacion a cristal de una sustancia activa de medicamen- to
ATE224719T1 (de) Phosphatidsäure enthaltende zusammensetzungen
HUP9702479A2 (hu) A doxazosin-mezilát új polimorf módosulata (II. forma), eljárás előállítására és a vegyületet tartalmazó gyógyszerkészítmények
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
ATE40987T1 (de) Acetylenische phenoxypropanolderivate und pharmazeutische zusammensetzungen fuer die behandlung von bluthochdruck.
RU94000064A (ru) Новые 2-циано-3-гидроксипропенамиды, метод их получения и содержащие их фармацевтические композиции
NO20013499D0 (no) Farmasöytisk blanding omfattende en kombinasjon av en profen og andre aktive forbindelser
AU560948B2 (en) Production of 4-amino-6,7-dimethoxy-2-(4-(furo-2-yl)- piperazin-1-yl) quinazoline
ATE164166T1 (de) 5-alkyl, 5-(1-alkenyl) und 5-(1-alkynyl) pyrimidin-enthaltende oligodesoxynukleotide und pharmazeutische präparate enthaltend solche verbindungen
Mannerfelt On surgery of the rheumatoid hand: consensus and controversy
Bartlett The effect of decomposition on the lignin of plant materials
DE69416034D1 (de) Pharmazeutische Zubereitung zur rektalen Verabreichung von pharmakologisch wirksamen Verbindungen

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: HEUMANN PCS GMBH, DE

Free format text: FORMER OWNER(S): HEUMANN PHARMA GMBH., DE